Arcutis Biotherapeutics Inc (NASDAQ:ARQT) price closed lower on Monday, April 15, dropping -1.08% below its previous close.
A look at the daily price movement shows that the last close reads $10.20. The company’s 5Y monthly beta was ticking 1.14. Taking into account the 52-week price action we note that the stock hit a 52-week high of $15.40 and 52-week low of $1.76. The stock subtracted -7.77% on its value in the past month.
Arcutis Biotherapeutics Inc, which has a market valuation of $1.16 billion, is expected to release its quarterly earnings report May 07, 2024 – May 13, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ARQT a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.
The overview shows that ARQT’s price is at present -3.73% off the SMA20 and 5.71% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 47.75, with weekly volatility standing at 9.57%. The indicator jumps to 8.94% when calculated based on the past 30 days. Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s beta value is holding at 1.13, while the average true range (ATR) indicator is currently reading 0.96.
An analysis of the Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock in terms of its daily trading volume indicates that the 3-month average is 4.69 million.
Current records show that the company has 114.97M in outstanding shares. The insiders’ percentage holdings are 15.30% of outstanding shares while the percentage share held by institutions stands at 84.08%. But the 212.38% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
